Risk of infectious diseases and cutaneous tumours in solid organ recipients: A meta-analysis of literature

Table 1 Incidence of viral infections in solid organ recipients n (%)

Ref.	No. of cases/	Age (yr)	M/F	Median follow-	Therapy	HSV infections	VZV infections	HPV infections
	population			up time
Greenberg et al[53]	68/Kidney	NA	NA	NA	NA	10 (14.7)	NA	NA
Hogewoning et al[15]	134/Kidney	32.6 ± 10.3	80/54	NA	NA	9 (6.7)	24 (17.9)	NA
Bakr et al[11]	302/Kidney	35.9 ± 11.3	216/86	0.25-23 yr	Miscellaneous	9 (3)	3 (1)	33 (10.9)
Savoia et al[65]	286/Kidney	NA	273/163	9.3 (0.1-39.8) yr	66.7% combination therapy (tacrolimus in 90%)	11 (2.5)	NA	45 (10.3)
Belloni-Fortina et al[12]	161/Liver	47.4 ± 11	116/45	NA	NA	3 (2)	3 (2)	30 (19)
Lima et al[22]	53/Kidney	44	28/25	52.5% of patients over 5 yr	44% prednisone 31% mycophenolate	3 (5.7)	4 (7.5)	14 (26.4)

For each literature study has been indicated number of included patients, type of solid organ transplantation, median age, sex, median follow-up time after solid organ transplantation, type of immunosuppressive treatment and the percentage of patients affected by herpes simplex virus (HSV), varicella zoster virus (VZV) and human papilloma virus (HPV) infections. NA: Data non available in the considered study; M: Male; F: Female.